Uppsala, Sweden, 2014-09-12 08:29 CEST (GLOBE NEWSWIRE) --
The company has initiated the application process, as well as filed a registration statement with the United States Securities and Exchange Commission under the JOBS Act. The company’s shares are currently listed on NASDAQ OMX Stockholm and the Frankfurt Stock Exchange.
”The US is the largest pharmaceutical market in the world, and now that Oasmia has its first product - Paccal Vet®-CA1, for treatment of cancer in dogs - on the American market, we believe that there is an increased interest in the company among American investors. A final decision for a possible secondary listing will be made later this year”, commented Oasmia's CEO Julian Aleksov.
Mikael Widell, Vice President Communications
Mobile: +46 70 311 99 60
E-mail: mikael.widell@oasmia.com
